Assertio Presents Data On SYMPAZAN Showing How It is Being Used In Daily Clinical Practice To Treat Patients With Lennox-gastaut Syndrome

Author: Benzinga Newsdesk | September 15, 2025 09:04am

• New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a severe form of childhood-onset epilepsy
• Study addresses lack of awareness and real-world data with oral film formulation of clobazam
• New data presented during poster session at 150th Annual Meeting of the American Neurological Association
• SYMPAZAN is the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with LGS in patients two years of age or older

Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today announced new data from a first-ever real-world study of SYMPAZAN (clobazam) Oral Film.

The data were presented at the 150th Annual Meeting of the American Neurological Association (ANA2025) as a poster (click here for poster) titled "M266: Real-World Evidence Study of Patients with Lennox-Gastaut Syndrome Taking Clobazam Oral Soluble Film: Demographics, Medications, and Comorbidities."

Howard Franklin, M.D., Senior Vice President of Medical with Assertio: "This is the first data of its kind for Sympazan, showing how this medicine is being applied in daily clinical practice to treat patients with seizures associated with LGS. The findings support the role that an oral film formulation can play in treating LGS patients who have swallowing difficulties and cannot reliably take tablets or liquids."

Steven M. Wolf, M.D., Department of Pediatric Neurology, Boston Children's Health Physicians, Department of Neurology, Westchester Medical Center, Valhalla, NY, and a study author: "Clobazam can be an important treatment for LGS patients, which is a severe form of childhood-onset epilepsy that can be debilitating. This study allows the medical community to view real-world data about utilization of the oral film formulation offered by Sympazan and can help clinicians better understand how to incorporate the medicine in treatment regimens."

Posted In: ASRT